Key facts
- D3 Bio presented first-line data for elisrasib at ASCO 2026.
- Elisrasib monotherapy showed a 78.0% ORR and 12.4 months median PFS in first-line KRAS G12C-mutant NSCLC.
D3 Bio presented preliminary data for elisrasib, a KRAS G12C inhibitor, in first-line NSCLC. Monotherapy showed a 78.0% ORR and 12.4 months median PFS. The combination with pembrolizumab achieved an 81.3% ORR. Safety was described as manageable.
D3 Bio presented data for its drug elisrasib (D3S-001) at ASCO 2026. Elisrasib is a next-generation KRAS G12C inhibitor. The data focused on its efficacy in the first-line treatment of non-small cell lung cancer (NSCLC) with KRAS G12C mutations.
D3 Bio presented data for its drug elisrasib (D3S-001) at ASCO 2026. Elisrasib is a next-generation KRAS G12C inhibitor. The data focused on its efficacy in the first-line treatment of non-small cell lung cancer (NSCLC) with KRAS G12C mutations.
Pick the topics you care about. Get only what matters, on your cadence.